Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City

Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the leader in total artificial heart technology for patients with end-stage heart failure [3] - SynCardia's Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it is the only commercially available artificial heart in the United States and Canada [3] - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [3] Upcoming Events - Picard Medical will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York, NY [1] - Patrick NJ Schnegelsberg, CEO of Picard Medical, will be available for one-on-one meetings with investors during the event [2]